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OBJECTIVES: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder 
prevalent in up to 35% of the adult population in Mexico, thus rendering high costs 
for health institutions. Tegaserod, a 5-HT4 receptor agonist approved for the treatment 
of IBS, could potentially render a beneﬁ cial economic impact. An economic evaluation 
was performed to assess the economic impact of treating IBS patients with tegaserod 
in comparison to standard therapy in an institutional setting in Mexico. METHODS: 
A cost-effectiveness analysis was performed within an institutional setting (Mexican 
Institute of Social Security, IMSS). The drug comparator used was butylhyoscine, as 
it is the recommended standard therapy available in the National Formulary, as 
published in the institution’s IBS clinical guidelines. Resource utilization data was 
obtained from previous studies; physician consults, drug usage, laboratory tests, 
endoscopic procedures, non-endoscopic diagnostic procedures, and surgical proce-
dures were used for the analysis; a triangular probability distribution was used. Efﬁ -
cacy data was obtained from published meta-analysis studies. The source of the unit 
costs was the institution, current for 2009. Discount rate was not used because the 
time horizon was for 1 year. a probabilistic sensibility analysis was obtained through 
a Monte Carlo simulation with 100,000 iterations in the weakest parameters. 
RESULTS: The expected annual cost with standard therapy was $19,431.92 per 
patient in local currencies (Mexican Pesos, MXP), as compared to $18,394.68 with 
tegaserod therapy. Tegaserod was more effective than the standard therapy. Probabi-
listic sensibility analysis showed the same conclusions, regardless of the variability in 
resource utilization and efﬁ cacy. CONCLUSIONS: From an institutional perspective 
in Mexico, tegaserod is a cost-effective therapeutic option (dominant) for the treatment 
of IBS in comparison with the current standard therapy featured in the National 
Formulary.
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OBJECTIVES: To assess the cost-effectiveness of tests for diagnosing celiac disease 
(CD). The following tests were assessed: biopsy; endomysial antibody (EMA); anti-
gliadin antibody (AGA); deaminated gliadin peptide (DGP); tissue transglutaminase 
(TTG); and panel of tests. METHODS: A decision analysis was constructed to 
compare costs and outcomes based on sensitivity, speciﬁ city and prevalence estimates 
from a primary systematic literature review. Study results were pooled using a bivari-
ate, binomial, generalized linear mixed model (SAS 9.2). The target population was 
adults and children experiencing symptoms consistent with CD. Biopsy was assumed 
to have sensitivity and speciﬁ city of 1 since it is considered the gold standard. In 
serologic testing strategies the positive cases (true or false) were assumed to be con-
ﬁ rmed with biopsy. a family physician consult was incurred with serologic testing and 
a gastroenterologist consult was incurred with biopsy. The outcome of the analysis 
was expected costs and false negatives (FN). Costs were reported in 2010 CAD$. All 
analyses were performed using TreeAge Pro Suite 2009. RESULTS: Four strategies 
made up the efﬁ ciency frontier; IgGTTG, IgATTG, EMA and biopsy. All other strate-
gies were either strictly or extendedly dominated. IgGTTG was the least costly and 
least effective strategy ($178.95, 0.1553 FNs). Biopsy was the most costly and most 
effective strategy ($396.60, 0 FNs). The cost per FN avoided moving from IgGTTG 
to the other strategies sequentially on the efﬁ ciency frontier were $293, $369, $1401 
for EMA, IgATTG and biopsy respectively. One-way sensitivity analyses did not 
change the ranking of strategies. CONCLUSIONS: All testing strategies with biopsy 
were cheaper than biopsy alone however they also resulted in more FNs. If a decision 
maker’s willingness to pay to avoid a FN result is $1401 or greater, then biopsy alone 
is the most cost-effective strategy. Otherwise, either IgGTTG, IgATTG or EMA is the 
most cost-effective strategy.
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BACKGROUND: Chronic hepatitis B (CHB), affects 350–400 million people world-
wide, being associated with increased risk of liver failure and approximately 300,000 
cases of hepatocellular carcinoma per year. Treatment with pegylated interferon (48 
weeks) is associated with the possibility of sustained disease remission, with no need 
for maintenance with any other drug. Furthermore, on-treatment monitoring of 
HBsAg can predict response to peginterferon–alfa-2a (Lau 2009). Currently, only 
entecavir is available for HBeAg-positive chronic hepatitis B cirrhotic patients under 
Brazilian Public Healthcare System. OBJECTIVES: To compare costs and outcomes 
of on-treatment monitoring of HBsAG levels during peginterferon–alfa-2a therapy 
versus standard entecavir treatment of CHB under Brazilian Public Healthcare System 
perspective.  METHODS: To project disease progression, a Markov model was built 
based on clinical stages of CHB. a stopping rule was applied to peginterferon–alfa-2a 
scenario at week 12 based on efﬁ cacy results from Lau 2009: if HBsAg > 20000 UI/
ml, treatment is switched to 2nd line treatment (tenofovir). Medical resources related 
to each stage were obtained from Castelo, 2007. Efﬁ cacy of entecavir was obtained 
from Veenstra, 2007 & 2008. Tenofovir was also available as 2nd line treatment for 
entecavir scenario. Discount rate for costs and outcomes was 5%, according to Brazil-
ian guidelines for HTA. Costs were reported in 2010 Brazilian Reais (US$1 ≈ $Brz1.8). 
RESULTS: Assuming a lifetime perspective, expected costs and outcomes for pegin-
terferon-alfa-2a were: $Brz 38,605, 15.37 LYs and 13.64 QALYs. For entecavir: $Brz 
39,630, 15.20 LYs and 13.41 QALYs. Cost-effectiveness analysis estimated an ICER 
of (-$Brz37,614/LYs) and (-$Brz15,556/QALYs) for peginterferon-alfa-2a, being the 
dominant therapy. CONCLUSIONS: Considering on treatment monitoring of HBsAg, 
ﬁ ndings suggest that peginterferon–alfa-2a shows higher clinical responses and is a 
cost saving therapy for the management of CHB patients in the Brazilian Public 
Healthcare System.
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OBJECTIVES: Stapled hemorrhoidopexy (SH) offers several beneﬁ ts over conven-
tional excisional hemorrhoidectomy, which makes it attractive to patients with symp-
tomatic prolapsing piles, yet its provision remains disparate. a full economic evaluation 
of stapled hemorrhoidopexy was undertaken to establish its cost-effectiveness and take 
into consideration recent literature on clinical outcomes to show that the SH procedure 
can become cost-saving compared to CH (conventional hemorrhoidectomy). 
METHODS: A cost–utility analysis was undertaken to compare the use of SH with 
CH.The analysis used a probabilistic, cohort-based decision tree within a 1-year time-
horizon. Costs were analyzed from hospital and UK NHS perspective and utility was 
calculated using Quality Adjusted Life-years (QALY). Sensitivity analyses were used 
to show how variation in the clinical parameters affects cost-effectiveness. RESULTS: 
The decrease in time in the operating theatre and shorter hospital stay with SH led to 
a cost saving of £27 per procedure compared to CH on a hospital level. From the 
NHS perspective the total treatment costs inclusive of the cost of recurrent prolapse, 
led to an incremental cost of £33 after one year. Calculation of QALYs induced an 
incremental QALY of 0.0076 and showed an ICER of £4,316, which is a highly cost-
effective result. Sensitivity analysis taking into account recent publications showed 
that the SH procedure becomes cost saving with a reduction in recurrence rate of 
prolapse from 10% to 5% or a 50% reduction in re-surgery rate. CONCLUSIONS: 
Stapled hemorrhoidopexy is a cost-effective procedure with an incremental cost-
effective ration (ICER) of £4136. Furthermore the analysis also showed that stapled 
hemorrhoidopexy could even be cost-saving in UK clinical practice. This economic 
analysis, in line with the 2007 NICE guidance, supports its widespread 
implementation.
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OBJECTIVES: In Norway, proton pump inhibitor (PPI) therapy for GERD can only 
be reimbursed for patients with a diagnosis veriﬁ ed by gastroscopy or pH-metry. The 
purpose of this study (NCT00842387) was to evaluate the economic aspects of an 
alternative, structured treatment pathway based on GerdQ—a validated PRO tool for 
the diagnosis and treatment decisions in GERD. METHODS: Two treatment path-
ways in patients presenting with reﬂ ux, but no alarm symptoms were evaluated in an 
open randomized, parallel-group 8 week study. In the New Structured Pathway (NSP) 
diagnosis and treatment were based on GerdQ scores dividing patients into high 
impact GERD (treated with esomeprazole 40 mg), medium impact GERD (treated 
with generic PPI) and low probability of GERD (treated at the physician’s discretion). 
In the Ordinary Clinical Pathway (OCP), the physician was kept blinded to the GerdQ 
score and diagnosis was based on ﬁ ndings at gastroscopy or, if needed, pH-metry. 
Treatment was given according to normal clinical practice. Direct medical cost was 
estimated based on diagnostic procedures, medication and unscheduled health care 
visits. RESULTS: Treatment success with NSP diagnostic method was not inferior to 
OCP. The response rates were 86.5% and 80.1%, respectively. The health economic 
evaluation could thus be performed as a cost-minimization analysis. More patients in 
the NSP arm were treated with esomeprazole 40 mg than in the OCP arm (28.4% vs. 
10.2%); however, fewer health care visits and diagnostic procedures were seen. The 
average direct medical cost in the NSP arm was c51 per patient (NOK 410) compared 
with c390 (NOK 3139) in the OCP arm. CONCLUSIONS: By integrating the New 
Structured Pathway into clinical practice, direct health care resource use may be 
reduced without any loss in clinical effectiveness. 
